Nabumetone (Relitone)
Nabumetone
Pharmacare limited û woodmead
Every registration of this product has been cancelled.
Registration
- Applicant
- Pharmacare limited û woodmead
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Relitone* EACH TABLET CONTAINS NABUMETONE 500 mg | Not listed | 27010527/3.1/0105 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Nabumetone
- except when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S2)
Consolidated Schedules 06 July 2026, lines 3971 to 3972
S2: Nabumetone
- when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S3)
Consolidated Schedules 06 July 2026, lines 2363 to 2364
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
4-(6-Methoxynaphthalen-2-yl)butan-2-one
Drag to rotate. Structure from PubChem CID 4409.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.